US 11,911,351 B2
Methods for treating sleep apnea with combinations of atomoxetine and (R)-oxybutynin
Lawrence G. Miller, Cambridge, MA (US); Barry Wohl, Cambridge, MA (US); and Walter J. Lunsmann, Harvard, MA (US)
Assigned to APNIMED, INC. (DELAWARE), Cambridge, MA (US)
Appl. No. 16/965,960
Filed by Apnimed, Inc. (Delaware), Cambridge, MA (US)
PCT Filed Jan. 30, 2019, PCT No. PCT/US2019/015781
§ 371(c)(1), (2) Date Jul. 29, 2020,
PCT Pub. No. WO2019/152475, PCT Pub. Date Aug. 8, 2019.
Claims priority of provisional application 62/623,892, filed on Jan. 30, 2018.
Prior Publication US 2021/0038541 A1, Feb. 11, 2021
Int. Cl. A61K 31/138 (2006.01); A61K 31/216 (2006.01); A61P 11/00 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/138 (2013.01) [A61K 31/216 (2013.01); A61P 11/00 (2018.01); A61K 45/06 (2013.01)] 25 Claims
OG exemplary drawing
 
8. A method of treating obstructive sleep apnea in a subject in need thereof, the method comprising administering to the subject an effective amount of a combination of (i) Atomoxetine and (ii) substantially enantiomerically pure (R)-oxybutynin, wherein the enantiomeric excess of the (R)-oxybutynin relative to its opposite enantiomer is greater than or equal to 90%.